Atezolizumab (Tecentriq▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)

Cases of severe cutaneous adverse reactions, including Stevens-Johnsons syndrome and toxic epidermal necrolysis have been reported in patients treated with these drugs. Patients should be advised to be vigilant for such skin reactions and seek urgent medical advice if they occur.

Source:

Medicines and Healthcare products Regulatory Agency